CUHK_CCT00005
2005-11-14
Retrospective
N/A
1) Lee Hysan Foundation Research Grant and Endowment Fund Research Grant 2003/2004 (United College, CUHK) 2) RGC Research Grant Direct Allocation 2004 (CUHK)
N/A
N/A
Prof. Tam Wing Hung
1E,Department of O&G, Prince of Wales Hospital, Shatin, N.T., Hong Kong
852 2632 2802
tamwh@cuhk.edu.hk
Associate Professor
Prof. Tam Wing Hung
1E,Department of O&G, Prince of Wales Hospital, Shatin, N.T., Hong Kong
852 2632 2802
tamwh@cuhk.edu.hk
Associate Professor
Clinical and Metabolic Effects of Rosiglitazone on Women with Polycystic Ovarian Syndrome
Clinical and Metabolic Effects of Rosiglitazone on Women with Polycystic Ovarian Syndrome
N/A
Hong Kong
Yes
2004-04-20
Polycystic Ovarian Syndrome
Other
Rosiglitazone
Rosiglitazone 4mg B.D. (8mg per day)
12 months
Placebo 1 tab B.D.
INCLUSION CRITERIA: (At least 2 of the major criteria listed below) Major criteria: 1) Anovulation (with other causes of anovulation excluded); 2) Clinical signs of hyperandrogenism (hirsutism or acne) and/or hyperandrogenemia (with other causes of hyperandrogenemia excluded); Minor criteria: 1) Elevated early follicular phase (LH >10 IU/L); 2) Elevated LH/FSH ratio (>2.5); 3) Polycystic ovaries on ultrasound scan 4) Obesity (BMI > 25) / Insulin resistance
EXCLUSION CRITERIA: 1) Women with PCOS who are planning for pregnancy, or undergoing fertility treatment; 2) Women with PCOS who are already on oral hypoglycaemic agents or insulin treatment; 3) Women with cardiovascular disease, hepatic or renal function impairment; 4) Women on corticosteroid therapy; 5) Women with known endometrial hyperplasia
N/A
N/A
Female
Interventional
Randomized
Placebo
Double-blind
Parallel
2004-11-18
70
Complete
Menstrual status; hirsutism score, free testosterone, SHBG level
IMT (Intima Madia Thickness)
2009-12-04
ChiCTR-TRC-09000670
2010-05-04
|
|
|
|
---|---|---|---|
No documents yet. |